A Phase 3 interventional study of Secukinumab and Placebo in Tendinopathy, sponsored by Novartis Pharmaceuticals. Completed at 19 sites in Germany. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-23.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Tendinopathy with a site in Germany — 2 open to participants now, 2 under way, none of them phase 3. Tendinopathy · Germany.
Among the 11 studies in Tendinopathy with a site in Germany, this one is the 6th largest by enrollment of the 10 interventional ones that give a count, is the only one that started in 2022, is one of 3 in phase 3, and was the 8th registered.
397 studies on the registry are indexed under Tendinopathy; 77 are open to participants now.
Browse Tendinopathy studies →2 of the 11 studies in Tendinopathy with a site in Germany are open now. Recruiting first, the newest first:
TRB Chemedica AG · Sites in Germany
Ages 18–99
Gymna Uniphy · Sites in Germany
Ages 18–59
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 47 Tendinopathy studies recruiting now, 17 (36%) set no upper age limit and 23 (49%) stop at 75 or younger; 1 takes children under 18; 7 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 1 started in 2022.
This study's enrollment of 62 is above the median of 48 across 332 interventional studies indexed under Tendinopathy.
Median enrollment 66 across the 10 interventional studies, 84 across the 1 observational. Of the 6 that completed or were terminated, 2 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 11 have an industry lead sponsor. The 5 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
Novartis has 5 studies filed under Tendinopathy — fewer than ten, so there is no comparison to draw.
1 of the studies in Tendinopathy with a site in Germany that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06681051TRB Chemedica AGEffectiveness and Safety of OSTENIL® TENDON in the Treatment of Pain and Restricted Mobility in Tendon Disorders | 2027-10 |
Add it to your calendar (.ics) → With an account.
Among the 11 studies in Tendinopathy with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study was to investigate the efficacy and safety of secukinumab subcutaneously (s.c.) compared to placebo in adult patients with moderate to severe rotator cuff tendinopathy and failure to conventional therapy.
This was a randomized, double-blind, placebo-controlled, parallel-group, multicenter, Phase IIIb, 24-week study to investigate the superior efficacy of secukinumab and safety in participants with rotator cuff tendinopathy.
Secukinumab 300 mg s.c. was compared to placebo (both arms in combination with patient individualized conventional therapy) in relieving clinical symptoms at Week 24.
The study consisted of a screening period up to 6 weeks, a 2-week run-in period, a 12-week treatment period and a 12-week follow-up period. Treatment and follow-up periods were blinded. Participants who met the eligibility criteria at screening continued to the run-in period and were randomized. In the run-in period, participants performed 2 weeks of home-based standardized physiotherapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Moderate to severe rotator cuff tendinopathy was demonstrated by all of the following criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received 300 mg of secukinumab s.c. for 12 weeks
Drug: Secukinumab
Participants received placebo s.c. for 12 weeks
Other: Placebo
Secukinumab 300 mg s.c for 12 weeks in a pre-filled syringe (PFS)
Also known as: AIN457
Placebo to match secukinumab s.c. for 12 weeks in a PFS
Change From Baseline in the Western Ontario Rotator Cuff (WORC) Patient Reported Outcome (PRO) Percentage Score at Week 24
The WORC Index consisted of 21 items divided into 5 Domains: Physical Symptoms (6 items), Sport/Recreation (4 items), Work Function (4 items), Lifestyle Function (4 items) and Emotional Function (3 items). Each of the 21 items in the WORC was rated using a visual analogue scale (VAS) ranging from 0 (no impact on quality of life) to 100 (worst possible impact). Thus, the total score ranged from 0 to 2100 points. The score was reported as a percentage of normal by subtracting the total score from 2100, dividing by 2100, and multiplying by 100. Total final WORC percentage scores ranged from 0%, the lowest functional status level, to 100%, the highest functional status level. Change from baseline in the WORC percentage total score was assessed at Week 24. A positive change from baseline indicated an improvement.
Time frame: Baseline, Week 24
Change From Baseline in the WORC Percentage Sub-scores at Week 24
The WORC Index consisted of 21 items divided into 5 Domains: Physical Symptoms (6 items), Sport/Recreation (4 items), Work Function (4 items), Lifestyle Function (4 items) and Emotional Function (3 items). Each of the 21 items in the WORC was rated using a VAS ranging from 0 (no impact on quality of life) to 100 (worst possible impact). Each subdomain score was calculated as a percentage of normal function, ranging from 0% (worst condition) to 100% (best condition). Change from baseline in the WORC Index percentage sub-domain score was assessed at Week 24. A positive change from baseline indicated an improvement
Time frame: Baseline, Week 24
Change From Baseline in Participant's Global Assessment of Disease Activity Score at Week 24
The participant's global assessment of disease activity was performed using 100 mm VAS ranging from 0="no activity" to 100= "most active", after the question " Please indicate with a vertical mark ( \| ) through the horizontal line the global activity of your disease in the last 24 hours". Change from baseline in the participant's global assessment of disease activity score was assessed at Week 24. A negative change from baseline indicated improvement
Time frame: Baseline, Week 24
Change From Baseline in Short Form 36 (SF-36v2) Score at Week 24
The SF-36 Health Survey was a validated questionnaire assessing health-related quality of life. Participants completed the survey throughout the study, reflecting their health status over the previous 4 weeks. It consisted of eight subscales that were scored individually; and two overall summary scores, the Physical Component Summary (PCS) and the Mental Component Summary (MCS). Component summary scores (PCS and MCS) were derived from weighted combinations of the eight subscales. Each domain and component summary score ranged from 0 to 100, with higher scores indicating better quality of life. Change from baseline to Week 24 in all subscale and summary scores was assessed, where a positive change indicated improvement.
Time frame: Baseline, Week 24
Change From Baseline in Quick Disability of the Arm, Shoulder and Hand (DASH) Questionnaire Score at Week 24
The QuickDASH was an abbreviated form of the DASH. The QuickDASH Index was self-administered and used 11 items to measure physical function and symptoms in participants with any or multiple musculoskeletal disorders of the upper limb. It had a recall period of 1 week. Each item of the QuickDASH had five response options. The raw score was calculated as the sum of responses, converted to an average, and rescaled to a total score ranging from 0 (no disability) to 100 (most severe disability) Change from baseline to Week 24 was assessed. A negative change from baseline indicated improvement.
Time frame: Baseline, Week 24
Change From Baseline in the Numeric Rating Scale (NRS) Pain Score at Week 24
The score for pain was assessed by using an 11-point NRS ranging from 0 "no pain at all" to 10 "worst possible pain", after the question "On a numeric scale of 0-10 where would you rate your pain at this time". Change from baseline to Wek 24 was assessed. A negative change from baseline indicated improvement
Time frame: Baseline, Week 24
Change From Baseline in EuroQol 5 Dimensions- 5 Levels (EQ-5D-5L) at Week 24- Total Score
The EQ-5D-5L was a standardized instrument used to evaluate patients' overall health-related quality of life (QoL). It consisted of two components: the descriptive system and the EQ visual analogue scale (EQ VAS). The descriptive system assessed five dimensions of health: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension was rated on five levels, from 1 (no problems) to 5 (extreme problems). These ratings were combined to generate a composite health index, which could be converted into a single summary health utility score using published value sets. Total scores ranged from 0 to 1, with lower scores indicating greater health impairment. Changes in total scores from baseline to Week 24 were analyzed, with positive changes indicating improvement in health-related quality of life.
Time frame: Baseline, Week 24
Change From Baseline in EuroQol 5 Dimensions- 5 Levels (EQ-5D-5L) at Week 24- EQ VAS
The EQ-5D-5L was a standardized instrument used to evaluate patients' overall health-related quality of life (QoL). It consisted of two components: the descriptive system and the EQ visual analogue scale (EQ VAS). The EQ VAS captured the respondent's self-rated health on a vertical scale ranging from 0 (worst imaginable health) to 100 (best imaginable health). Changes in EQ VAS scores from baseline to Week 24 were analyzed, with positive changes indicating improvement in health-related quality of life.
Time frame: Baseline, Week 24
Patients were randomized in 19 study sites across Germany
| Milestone | Secukinumab | Placebo |
|---|---|---|
| Started | 30 | 32 |
| Completed | 30 | 27 |
| Not completed | 0 | 5 |
| Withdrew: Adverse event | 0 | 1 |
| Withdrew: Lack of compliance | 0 | 1 |
| Withdrew: Withdrawal of consent | 0 | 1 |
| Withdrew: Participant wish | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 1 |
The WORC Index consisted of 21 items divided into 5 Domains: Physical Symptoms (6 items), Sport/Recreation (4 items), Work Function (4 items), Lifestyle Function (4 items) and Emotional Function (3 items). Each of the 21 items in the WORC was rated using a visual analogue scale (VAS) ranging from 0 (no impact on quality of life) to 100 (worst possible impact). Thus, the total score ranged from 0 to 2100 points. The score was reported as a percentage of normal by subtracting the total score from 2100, dividing by 2100, and multiplying by 100. Total final WORC percentage scores ranged from 0%, the lowest functional status level, to 100%, the highest functional status level. Change from baseline in the WORC percentage total score was assessed at Week 24. A positive change from baseline indicated an improvement.
| Score on a Scale | Secukinumab | Placebo |
|---|---|---|
| Change From Baseline in the Western Ontario Rotator Cuff (WORC) Patient Reported Outcome (PRO) Percentage Score at Week 24 | 55.7 ± 28.1 | 46.8 ± 26.9 |
The WORC Index consisted of 21 items divided into 5 Domains: Physical Symptoms (6 items), Sport/Recreation (4 items), Work Function (4 items), Lifestyle Function (4 items) and Emotional Function (3 items). Each of the 21 items in the WORC was rated using a VAS ranging from 0 (no impact on quality of life) to 100 (worst possible impact). Each subdomain score was calculated as a percentage of normal function, ranging from 0% (worst condition) to 100% (best condition). Change from baseline in the WORC Index percentage sub-domain score was assessed at Week 24. A positive change from baseline indicated an improvement
| Score on a Scale | Secukinumab | Placebo |
|---|---|---|
| Physical symptom score | 48.8 ± 31.2 | 40.0 ± 25.0 |
| Sports and recreation | 51.8 ± 30.9 | 44.0 ± 30.6 |
| Work | 59.7 ± 32.0 | 49.9 ± 30.5 |
| Lifestyle | 59.5 ± 27.3 | 52.9 ± 26.4 |
| Emotional function | 64.2 ± 23.6 | 54.3 ± 31.5 |
The participant's global assessment of disease activity was performed using 100 mm VAS ranging from 0="no activity" to 100= "most active", after the question " Please indicate with a vertical mark ( \| ) through the horizontal line the global activity of your disease in the last 24 hours". Change from baseline in the participant's global assessment of disease activity score was assessed at Week 24. A negative change from baseline indicated improvement
| Score on a scale | Secukinumab | Placebo |
|---|---|---|
| Change From Baseline in Participant's Global Assessment of Disease Activity Score at Week 24 | -46.4 ± 36.6 | -18.5 ± 37.2 |
The SF-36 Health Survey was a validated questionnaire assessing health-related quality of life. Participants completed the survey throughout the study, reflecting their health status over the previous 4 weeks. It consisted of eight subscales that were scored individually; and two overall summary scores, the Physical Component Summary (PCS) and the Mental Component Summary (MCS). Component summary scores (PCS and MCS) were derived from weighted combinations of the eight subscales. Each domain and component summary score ranged from 0 to 100, with higher scores indicating better quality of life. Change from baseline to Week 24 in all subscale and summary scores was assessed, where a positive change indicated improvement.
| Score on a Scale | Secukinumab | Placebo |
|---|---|---|
| Physical component summary | 9.4 ± 9.1 | 9.7 ± 7.9 |
| Mental component summary | 8.0 ± 10.7 | 6.3 ± 11.9 |
| General health | 3.0 ± 8.5 | 3.9 ± 10.6 |
| Vitality | 8.3 ± 9.9 | 7.7 ± 11.0 |
| Social functioning | 8.3 ± 10.1 | 8.2 ± 10.9 |
| Role emotional | 11.5 ± 13.1 | 5.8 ± 14.5 |
| Mental health | 7.6 ± 10.0 | 9.1 ± 10.9 |
| Physical function | 8.8 ± 9.5 | 8.6 ± 6.4 |
| Role-physical | 9.9 ± 10.3 | 9.3 ± 10.9 |
| Bodily pain | 16.2 ± 10.2 | 15.1 ± 9.2 |
The QuickDASH was an abbreviated form of the DASH. The QuickDASH Index was self-administered and used 11 items to measure physical function and symptoms in participants with any or multiple musculoskeletal disorders of the upper limb. It had a recall period of 1 week. Each item of the QuickDASH had five response options. The raw score was calculated as the sum of responses, converted to an average, and rescaled to a total score ranging from 0 (no disability) to 100 (most severe disability) Change from baseline to Week 24 was assessed. A negative change from baseline indicated improvement.
| Score on a Scale | Secukinumab | Placebo |
|---|---|---|
| Change From Baseline in Quick Disability of the Arm, Shoulder and Hand (DASH) Questionnaire Score at Week 24 | -34.1 ± 23.7 | -33.5 ± 24.6 |
The score for pain was assessed by using an 11-point NRS ranging from 0 "no pain at all" to 10 "worst possible pain", after the question "On a numeric scale of 0-10 where would you rate your pain at this time". Change from baseline to Wek 24 was assessed. A negative change from baseline indicated improvement
| Score on a Scale | Secukinumab | Placebo |
|---|---|---|
| Change From Baseline in the Numeric Rating Scale (NRS) Pain Score at Week 24 | -4.5 ± 2.8 | -4.6 ± 2.4 |
The EQ-5D-5L was a standardized instrument used to evaluate patients' overall health-related quality of life (QoL). It consisted of two components: the descriptive system and the EQ visual analogue scale (EQ VAS). The descriptive system assessed five dimensions of health: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension was rated on five levels, from 1 (no problems) to 5 (extreme problems). These ratings were combined to generate a composite health index, which could be converted into a single summary health utility score using published value sets. Total scores ranged from 0 to 1, with lower scores indicating greater health impairment. Changes in total scores from baseline to Week 24 were analyzed, with positive changes indicating improvement in health-related quality of life.
| Score on a Scale | Secukinumab | Placebo |
|---|---|---|
| Change From Baseline in EuroQol 5 Dimensions- 5 Levels (EQ-5D-5L) at Week 24- Total Score | 0.265 ± 0.226 | 0.342 ± 0.228 |
The EQ-5D-5L was a standardized instrument used to evaluate patients' overall health-related quality of life (QoL). It consisted of two components: the descriptive system and the EQ visual analogue scale (EQ VAS). The EQ VAS captured the respondent's self-rated health on a vertical scale ranging from 0 (worst imaginable health) to 100 (best imaginable health). Changes in EQ VAS scores from baseline to Week 24 were analyzed, with positive changes indicating improvement in health-related quality of life.
| Score on a Scale | Secukinumab | Placebo |
|---|---|---|
| Change From Baseline in EuroQol 5 Dimensions- 5 Levels (EQ-5D-5L) at Week 24- EQ VAS | 18.3 ± 36.5 | 23.8 ± 27.3 |
Collected over From start of treatment to end of study, assessed up to approximately 24 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Secukinumab | 0/30 (0%) | 2/30 (6.7%) | 22/30 (73.3%) |
| Placebo | 0/32 (0%) | 3/32 (9.4%) | 24/32 (75%) |
| Event | Secukinumab | Placebo |
|---|---|---|
| Oropharyngeal candidiasisInfections and infestations | 1/30 | 0/32 |
| DepressionPsychiatric disorders | 1/30 | 0/32 |
| Vaginal cuff dehiscenceInjury, poisoning and procedural complications | 0/30 | 1/32 |
| Lipase increasedInvestigations | 0/30 | 1/32 |
| Pancreatic neuroendocrine tumourNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/30 | 1/32 |
| Occipital lobe strokeNervous system disorders | 0/30 | 1/32 |
| Paradoxical embolismVascular disorders | 0/30 | 1/32 |
| Event | Secukinumab | Placebo |
|---|---|---|
| ArthralgiaMusculoskeletal and connective tissue disorders | 3/30 | 11/32 |
| HeadacheNervous system disorders | 8/30 | 6/32 |
| NasopharyngitisInfections and infestations | 5/30 | 7/32 |
| COVID-19Infections and infestations | 4/30 | 3/32 |
| Back painMusculoskeletal and connective tissue disorders | 4/30 | 3/32 |
| HypertensionVascular disorders | 3/30 | 2/32 |
| BronchitisInfections and infestations | 0/30 | 3/32 |
| Gastrointestinal infectionInfections and infestations | 2/30 | 0/32 |
| Oral herpesInfections and infestations | 2/30 | 2/32 |
| Respiratory tract infectionInfections and infestations | 2/30 | 0/32 |
| Age, Continuous(years) | Secukinumab | Placebo | Total |
|---|---|---|---|
| Mean | 52.3 ± 7.5 | 52.1 ± 9.0 | 52.2 ± 8.2 |
| Sex: Female, Male(Participants) | Secukinumab | Placebo | Total |
|---|---|---|---|
| Female | 20 | 15 | 35 |
| Male | 10 | 17 | 27 |
| Race/Ethnicity, Customized(Participants) | Secukinumab | Placebo | Total |
|---|---|---|---|
| Caucasian | 29 | 31 | 60 |
| Black | 1 | 0 | 1 |
| Asian | 0 | 1 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Ran from Dec 2022 to primary completion in Dec 2024, 24 months.
Results were first posted in Dec 2025, 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Secukinumab